Acelyrin, Inc. (SLRN)
| Market Cap | 262.35M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -248.23M |
| Shares Out | 100.71M |
| EPS (ttm) | -2.50 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 177,084 |
| Open | 2.630 |
| Previous Close | 2.640 |
| Day's Range | 2.560 - 2.640 |
| 52-Week Range | 1.845 - 7.250 |
| Beta | n/a |
| Analysts | Hold |
| Price Target | 9.60 (+268.52%) |
| Earnings Date | Mar 19, 2025 |
About SLRN
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company’s lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R for the treatment of Thyroid Eye Disease (TED), which is in Phase 2. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for SLRN stock is "Hold." The 12-month stock price forecast is $9.6, which is an increase of 268.52% from the latest price.
News
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan
LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines ...
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC...
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger
All-Stock Transaction with Alumis Maximizes Long-Term Value for ACELYRIN Stockholders LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma com...
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines i...
ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acelyrin, Inc. (...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.
NEW YORK , Feb. 7, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by ACELYRIN, INC. (NASDAQ: SLRN) and its board of directors concerning the proposed acquisi...
Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mostly higher this morning, with the Dow futures gaining around 0.1% on Tuesday.
ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease
Totality of data observed with subcutaneous lonigutamab in Thyroid Eye Disease (TED) patients demonstrate potential for efficacy in line with standard of care and a more favorable safety profile
ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab
LOS ANGELES, Jan. 02, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines i...
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
Phase 2b/3 trial of izokibep did not meet primary endpoint; secondary endpoints also did not achieve statistical significance
Acelyrin, Inc. (SLRN) Q3 2024 Earnings Call Transcript
Acelyrin, Inc. (NASDAQ:SLRN) Q3 2024 Earnings Call November 13, 2024 4:30 PM ET Company Participants Tyler Marciniak - Vice President, Investor Relations and Corporate Affairs Mina Kim - Chief Execut...
ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights
Topline data from Phase 2b/3 trial of izokibep as a treatment for non-infectious non-anterior uveitis expected in December 2024
ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024
LOS ANGELES, Nov. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines i...
Acelyrin: Straight Move To Phase 3 TED Studies Makes It Must Watch
Acelyrin, Inc. shifts focus to developing lonigutamab for thyroid eye disease, aiming for phase 3 trials in Q1 2025, bypassing phase 2b/3 studies. Key catalysts include an end-of-phase 2 meeting and a...
ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024
LOS ANGELES, Sept. 19, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines ...
ACELYRIN, INC. to Participate in Upcoming Investor Conferences
LOS ANGELES, Aug. 22, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines i...
Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep
On Wednesday, Acelyrin Inc. SLRN confirmed that it was completing a 33% reduction in its workforce.
Acelyrin, Inc. (SLRN) Q2 2024 Earnings Call Transcript
Acelyrin, Inc. (NASDAQ:SLRN) Q2 2024 Earnings Conference Call August 13, 2024 5:00 PM ET Company Participants Tyler Marciniak - Vice President of Investor Relations and Corporate Affairs Mina Kim - C...
ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024
LOS ANGELES, Aug. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines i...
ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024
Lonigutamab is the first subcutaneous anti-IGF-1R to demonstrate clinical responses in thyroid eye disease (TED) patients
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
Completed enrollment in izokibep Phase 3 trial in hidradenitis suppurativa and enrollment completion in Phase 2b/3 trial in uveitis expected this month; top line data for both trials now expected by e...
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
LOS ANGELES, April 29, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines ...
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
Reported positive Phase 1/2 proof-of-concept data for lonigutamab, first subcutaneous anti-IGF-1R to demonstrate clinical responses in thyroid eye disease patients
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
Study met primary endpoint of ACR50 at 16 weeks versus placebo with high statistical significance and is expected to be the first of two registrational trials in psoriatic arthritis
ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients
Dose ordered and robust HiSCRs were rapidly demonstrated with about a third of patients achieving HiSCR100, or resolution of abscesses and nodules, by week 16 and through week 32